Three Biotech Stocks Working On CAR-T Immunotherapy You Ought To See

Source: Juno Therapeutics.

Last week, Celgene Corp. (NASDAQ:CELG) shocked biotech investors when it agreed to pay $1 billion for $850 million worth of Juno Therapeutics‘ (NASDAQ:JUNO) stock and a handful of licensing rights, leaving Celgene with a 10% stake in the smaller company. Continue reading Three Biotech Stocks Working On CAR-T Immunotherapy You Ought To Witness – The Motley Loser